© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Conference Coverage
It’s been a good year for heart failure research … mostly
EXPERT ANALYSIS FROM ACC 17
Related Articles
![1]()
Empagliflozin cut PA pressures in heart failure patients
April 13, 2017
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
New study of diabetes drug for COVID-19 raises eyebrows
April 13, 2017
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
Cardiogenic shock teams again tied to lower mortality
April 13, 2017
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.
![1]()
Pneumonia risk soars in heart failure patients, especially HFpEF
April 13, 2017
An analysis of two large trials found that patients with heart failure have an elevated risk of pneumonia and related adverse cardiovascular events.
